Eric Ostertag - 01 Feb 2023 Form 4 Insider Report for Poseida Therapeutics, Inc.

Role
Director
Signature
/s/ Harry J. Leonhardt, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
01 Feb 2023
Net transactions value
-$82,432
Form type
4
Filing time
03 Feb 2023, 15:19:36 UTC
Previous filing
17 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PSTX Common Stock Tax liability $82,432 -11,776 -1.4% $7.00 827,320 01 Feb 2023 Direct F1
holding PSTX Common Stock 3,659,503 01 Feb 2023 See footnote F2
holding PSTX Common Stock 580,292 01 Feb 2023 See footnote F3
holding PSTX Common Stock 961,445 01 Feb 2023 See footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Eric Ostertag is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on February 1, 2022.
F2 The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee.
F3 The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person.
F4 The shares are held in the name of the Ostertag Family Trust dated March 30, 2016, of which the reporting person is a trustee.